OTCBB:MYMX

Mymetics Stock Insider Trading

> Biotechnology

Buy MYMX

*Your capital is at risk

$0.0003

+0 (+0%)

At Close: Jul 31, 2026

Mymetics Stock Insider Power

Based on the 82 latest insides trades, we have calculated the insider power to be negative at 0. In total, the insiders bought 65.37M and sold 10.13M MYMX shares in the last 82 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 82 transactions)	0
● Buy	65.37M shares
● Sell	10.13M shares
93% Buy Activity Negligible or No Correlation
No Significant Signals No statistically significant buy or sell signals detected in recent insider data.

Historical Insider Trades

Date	Type	Person	Role	Amount
Jun 17, 2010 Buy	Stock Options	Stegmann Antonius Johannes Cso	Officer	150 000 Value: $21.0K
Dec 31, 2009 Buy	Stock Options A-Award	Fleury Sylvain Cso	Officer	350 000 Value: $49.0K
Dec 31, 2009 Buy	Stock Options A-Award	Fleury Sylvain Cso	Officer	350 000 Value: $49.0K
Jul 20, 2009 Sell	Common Stock S-Sale	Rochet Christian Director	Director	1 917 276 Value: $334.2K
Jul 20, 2009 Sell	Common Stock S-Sale	Rochet Christian Director	Director	1 917 276 Value: $334.2K
Jun 23, 2008 Buy	Common Stock A-Award	Stern Ernest M Director	Director	500 000 Value: $0
Jun 23, 2008 Buy	Common Stock A-Award	Stern Ernest M Director	Director	500 000 Value: $0
Jun 10, 2008 Buy	Mymetics Common Stock	Martin Jacques Francois CEO	CEO / President	0 Value: $0
Jun 10, 2008 Buy	Mymetics Common Stock	Martin Jacques Francois CEO	CEO / President	0 Value: $0
Mar 17, 2008 Buy	Common Stock A-Award	Stern Ernest M Director	Director	500 000 Value: $0
Mar 17, 2008 Buy	Common Stock A-Award	Stern Ernest M Director	Director	500 000 Value: $0
Jan 21, 2008 Buy	Common Stock	Stern Ernest M Director	Director	0 Value: $0
Jan 21, 2008 Buy	Common Stock	Stern Ernest M Director	Director	0 Value: $0
Jul 02, 2007 Buy	Unsecured convertible note, 6/23/2006	Staehelin Thomas Director	Director	190 000 Value: $19.0K
Jul 02, 2007 Buy	Common stock	Staehelin Thomas Director	Director	0 Value: $0
Jul 02, 2007 Buy	Secured convertible note, 6/15/2009	Staehelin Thomas Director	Director	143 000 Value: $114.4K
Jul 02, 2007 Buy	Unsecured convertible note, 6/23/2006	Staehelin Thomas Director	Director	190 000 Value: $19.0K
Jul 02, 2007 Buy	Secured convertible note, 6/15/2009	Staehelin Thomas Director	Director	143 000 Value: $114.4K
Jul 02, 2007 Buy	Common stock	Staehelin Thomas Director	Director	0 Value: $0
Jun 18, 2007 Buy	Common Stock	Fleury Sylvain Cso	Officer	0 Value: $0
Jun 18, 2007 Buy	Common Stock	Fleury Sylvain Cso	Officer	0 Value: $0
Jun 18, 2007 Buy	Common Stock A-Award	Luebke Ernst Chief Financial Officer	C-Suite Officer	2 500 000 Value: $2.50M
Jun 18, 2007 Buy	Common Stock A-Award	Luebke Ernst Chief Financial Officer	C-Suite Officer	2 500 000 Value: $0
Jun 18, 2007 Buy	Common Stock A-Award	Luebke Ernst Chief Financial Officer	C-Suite Officer	2 500 000 Value: $0
Jun 18, 2007 Buy	Common Stock A-Award	Luebke Ernst Chief Financial Officer	C-Suite Officer	2 500 000 Value: $2.50M

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT MYMETICS CORP.

Mymetics Corporation, a vaccine company, engages in the research and development of vaccines for infectious and life disabling diseases in Switzerland. The company's product pipeline includes various vaccine candidates, such as HIV-1/AIDS, Covid-19, intra nasal influenza, respiratory syncytial virus, malaria, and chikungunya. Mymetics Corporation has a collaboration agreement with Texas Biomedical Research Institute; PATH Malaria Vaccine Initiati...

Read Full Profile Here